Emerging drugs for idiopathic pulmonary fibrosis
- 31 October 2005
- journal article
- review article
- Published by Taylor & Francis Ltd in Emerging Drugs
- Vol. 10 (4), 707-727
- https://doi.org/10.1517/14728214.10.4.707
Abstract
Pulmonary fibrosis is often the end stage of chronic, persistent, low-level lung injury, either of known or unknown cause. The most severe form of pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF), a disease process of unknown aetiology and one that often leads to respiratory failure and death. At present there are no proven or effective drug therapies for IPF. Recent advances in understanding of disease pathogenesis have focused attention on drug targeting of fibrogenic pathways, as opposed to traditional anti-inflammatory approaches. In this report, the present status of drug development of a number of emerging antifibrotic strategies and agents that may prove more effective in the therapy of this progressive, debilitating and fatal disease are reviewed.Keywords
This publication has 101 references indexed in Scilit:
- Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosisJournal of Inorganic Biochemistry, 2004
- Smad-dependent and Smad-independent pathways in TGF-β family signallingNature, 2003
- Pirfenidone effectively reverses experimental liver fibrosisJournal of Hepatology, 2002
- Myofibroblasts and mechano-regulation of connective tissue remodellingNature Reviews Molecular Cell Biology, 2002
- Human antitransforming growth factor β2 monoclonal antibody—a new modulator of wound healing in trabeculectomy: A randomized placebo controlled clinical studyOphthalmology, 2002
- Human myofibroblastic hepatic stellate cells express Ca2+-activated K+ channels that modulate the effects of endothelin-1 and nitric oxideJournal of Hepatology, 2001
- Ras‐dependent and ‐independent regulation of reactive oxygen species by mitogenic growth factors and TGF‐β1The FASEB Journal, 2000
- A Preliminary Study of Long-Term Treatment with Interferon Gamma-1b and Low-Dose Prednisolone in Patients with Idiopathic Pulmonary FibrosisThe New England Journal of Medicine, 1999
- Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis.Thorax, 1989
- Natural History and Treated Course of Usual and Desquamative Interstitial PneumoniaThe New England Journal of Medicine, 1978